1 Min Read
ZURICH, Dec 22 (Reuters) - Roche Holding AG's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday.
"The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment," it said in a statement, adding all secondary endpoints were also met.
Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910, which represents a threat to more traditional treatments from Novo Nordisk and Shire. (Reporting by Michael Shields)